International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

By S. Miyakis, M. Lockshin, T. Atsumi, D. Branch, R. Brey, R. Cervera, R. Derksen, P. G. D. Groot, T. Koike, P. Meroni and 5 more. Journal of Thrombosis and Haemostasis, 2006

6,323 citations recorded by the source corpus.

Subfields: Hematology, Nephrology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/9d5cb399b72142337f322bf3c09b1a1d616f7dbc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

1. J. Smolen

Citations in the corpus

• Evaluation and treatment of recurrent pregnancy loss: a committee opinion. (2012, background): “The most recent recommendations from the antiphospholipid consensus group list several clinical events that should trigger testing for aPLs (Table 2) (23).”
• Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011, neutral): “A recent meta-anal- ysis of 13 studies, including 469 CVT cases and 3023 control subjects,28 reported a pooled OR of CVT of 3.38 (95% CI 2.27 to 5.05) for factor V Leiden, which is similar to its association with venous thromboembolism (VTE) in general.28”
• Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, background): “The APS should be suspected in a patient with TIA or ischemic stroke who has other features of the syndrome, such as livedo reticularis, obstetric complications, unexplained thrombocytopenia, or prolongation of a coagulation test.(686) An association between antiphospholipid antibodies and stroke ha”
• Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients (2009, methodology): “Patients were considered to have these manifestations if the diagnosis was firmly confirmed according to the established criteria for each manifestation using laboratory, imaging or Doppler studies or histopathology, with the exception of superficial venous thrombosis and other dermatological featur”
• ESHRE guideline: recurrent pregnancy loss (2018, background): “Conditional ⊕⊕⊕○ For women with RPL, we recommend screening for antiphospholipid antibodies (lupus anticoagulant [LA], and anticardiolipin antibodies [ACA IgG and IgM]), after two pregnancy losses (Miyakis et al., 2006; Opatrny et al., 2006).”
• High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study (2020, background): “Indeed, RRT circuit thrombosis, despite systemic anticoagulation by continuous infusion of heparin and/ or citrate [14] , may be explained by both the very high level of fibrinogen and the ultrafiltration, resulting in higher concentrations inside the dialyzer capillaries, rather than by contact pha”
• 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases (2020, methodology): “Recommendations and good practice statements (GPS) for use of contraception in women with rheumatic and musculoskeletal disease (RMD). aPL = antiphospholipid antibody (persistent moderate [Mod]–to- high–titer anticardiolipin or anti–β2- glycoprotein I antibody or persistent positive lupus anticoagul”
• EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (2007, background): “61 In patients receiving long-term glucocorticoid therapy, calcium and vitamin D may protect from bone mass loss.”
• Pathogenesis of antiphospholipid syndrome: understanding the antibodies (2011, background): “(1) aPL interact with endothelial cells, primarily through binding of β2GPI on the cell surface, and induce a procoagulant and proinflammatory endothelial phenotype.”